Key result
Measuring epicardial fat thickness via echocardiography is proposed as a subclinical marker of cardiovascular disease and a potential therapeutic target in patients with psoriasis.
Why the study?
Psoriasis increases the risk of cardiovascular disease, prompting interest in measuring epicardial fat tissue as a subclinical disease marker and potential therapeutic target.
Echocardiographic measurement of epicardial fat thickness is proposed as a subclinical marker of cardiovascular disease and a potential therapeutic target in patients with psoriasis.
Answers are grounded in this paper and cite their sources.
May support epicardial fat assessment for CVD risk in psoriasis; leaves open its value as therapeutic target.
Psoriasis is a chronic inflammatory disease affecting over 8 million Americans. Importantly, patients with psoriasis are at an increased risk of developing atherosclerosis, coronary artery disease, and myocardial infarctions. Several studies have suggested that psoriasis may be an independent risk factor for cardiovascular disease given their shared inflammatory properties and pathogenic similarities. Epicardial fat is also linked to cardiovascular disease and may be an independent risk factor for atherosclerosis. It has been proposed that measuring epicardial fat tissue may serve as a useful subclinical measure of cardiovascular disease in psoriasis patients. Echocardiography has been increasingly adopted as an accurate, minimally invasive, and cost-effective measure of determining the volume and thickness of epicardial fat. Using echocardiographic measures of epicardial fat thickness as a marker of cardiovascular disease and therapeutic target in psoriasis patients may provide clinicians with a means to better manage and hopefully prevent deleterious downstream effects.
No takes yet. Share an insight, caveat, or question.
Kamath et al. (2019) conducted a review in Psoriasis. Echocardiographic measurement of epicardial fat thickness was evaluated. Measuring epicardial fat thickness via echocardiography is proposed as a subclinical marker of cardiovascular disease and a potential therapeutic target in patients with psoriasis.
Synapse has enriched 10 related papers. Consider them for comparative context: